Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37

Rens Peeters, Jorge Cuenca-Escalona, Esther A. Zaal, Anna T. Hoekstra, Anouk C.G. Balvert, Marcos Vidal-Manrique, Niek Blomberg, Sjoerd J. van Deventer, Rinke Stienstra, Julia Jellusova, Martin Giera, Luciana Hannibal, Ute Spiekerkoetter, Martin ter Beest, Celia R. Berkers, Annemiek B. van Spriel*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Scopus)

Abstract

The importance of fatty acid (FA) metabolism in cancer is well-established, yet the mechanisms underlying metabolic reprogramming remain elusive. Here, we identify tetraspanin CD37, a prognostic marker for aggressive B-cell lymphoma, as essential membrane-localized inhibitor of FA metabolism. Deletion of CD37 on lymphoma cells results in increased FA oxidation shown by functional assays and metabolomics. Furthermore, CD37-negative lymphomas selectively deplete palmitate from serum in mouse studies. Mechanistically, CD37 inhibits the FA transporter FATP1 through molecular interaction. Consequently, deletion of CD37 induces uptake and processing of exogenous palmitate into energy and essential building blocks for proliferation, and inhibition of FATP1 reverses this phenotype. Large lipid deposits and intracellular lipid droplets are observed in CD37-negative lymphoma tissues of patients. Moreover, inhibition of carnitine palmitoyl transferase 1 A significantly compromises viability and proliferation of CD37-deficient lymphomas. Collectively, our results identify CD37 as a direct gatekeeper of the FA metabolic switch in aggressive B-cell lymphoma.

Original languageEnglish
Article number5371
JournalNature Communications
Volume13
Issue number1
DOIs
Publication statusPublished - 13 Sept 2022

Fingerprint

Dive into the research topics of 'Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37'. Together they form a unique fingerprint.

Cite this